SCHEMBL28056267

SCHEMBL28056267

FC(F)(F)c1ccc2ncoc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.49
DYRK1A Q13627 1/20 0.45
BACE1 P56817 1/20 0.44
ULK1 O75385 1/20 0.40
ULK2 Q8IYT8 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
EPHX2 P34913 3/20 0.39
SCN4A P35499 1/20 0.39
LMNA P02545 1/20 0.38
NOS3 P29474 1/20 0.37
NOS2 P35228 1/20 0.37
NPBWR1 P48145 2/20 0.37
CHRNB2 P17787 1/20 0.37
CHRNA4 P43681 1/20 0.37
NOTUM Q6P988 1/20 0.37
PIM1 P11309 1/20 0.37
PIM2 Q9P1W9 1/20 0.37
PARP1 P09874 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31391349 0.85 DYRK1A (0.45) KDM4EDYRK1ABACE1NPC1RAB9A
SCHEMBL4640466 0.85 DYRK1A (0.45) KDM4EDYRK1ABACE1NPC1RAB9A
SCHEMBL2614339 0.81 DYRK1A (0.45) DYRK1ANPC1RAB9ASMN1; SMN2LMNA
SCHEMBL23478832 0.78 DYRK1A (0.42) DYRK1AULK1ULK2NPC1RAB9A
SCHEMBL29802284 0.76 RAB9A (0.71) NPC1RAB9ASMN1; SMN2EPHX2LMNA
SCHEMBL26932194 0.76 RAB9A (0.71) NPC1RAB9ASMN1; SMN2EPHX2LMNA
SCHEMBL29118422 0.75 ULK1 (0.45) ULK1ULK2NPC1RAB9ASMN1; SMN2
SCHEMBL20066542 0.75 LMNA (0.43) DYRK1ANPC1RAB9ASMN1; SMN2LMNA
SCHEMBL1798498 0.74 DYRK1A (0.49) KDM4EDYRK1ABACE1ULK1ULK2
SCHEMBL28056200 0.73 NPC1 (0.43) DYRK1ANPC1RAB9ASMN1; SMN2SCN4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113365995-B Immunomodulators, compositions and methods thereof 贝达药业股份有限公司 2025-03-04 CN disclosed
US-11655225-B2 Antimycobacterial heterocyclic amides CRESTONE, INC. (US) 2023-05-23 US disclosed
CN-105431427-A Novel PDE4 inhibitor MEIJI SEIKA PHARMA CO LTD 2016-03-23 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11655225-B2 Antimycobacterial heterocyclic amides AADAC, CPS1, NAT1 KDM4E 2100/4885DYRK1A 3890/4885BACE1 4551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.